Financial PerformanceGenio’s overall market share increased to 25% in 3Q24 from 21% in 2Q24, showing growth in market presence.
Market ExpansionThe commercial launch of Genio in England with its first implants successfully performed highlights Nyxoah's expansion in the European market.
Product InnovationGenio, a first-of-its-kind hypoglossal neurostimulation device, is designed to treat obstructive sleep apnea and is already covered under the NHS Specialized Services Devices Programme.